B-cell Acute Lymphoblastic Leukemia (B-ALL)
Oncology·MeSH: Burkitt Lymphoma
Prevalence
8.0 / 100K
Incidence
1.8 / 100K/yr
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| AZD0486 | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for B-cell Acute Lymphoblastic Leukemia (B-ALL)?
BioSniper tracks 1 drug in development for B-cell Acute Lymphoblastic Leukemia (B-ALL) across 1 company.
How many clinical trials target B-cell Acute Lymphoblastic Leukemia (B-ALL)?
There are 3 clinical trials targeting B-cell Acute Lymphoblastic Leukemia (B-ALL) tracked by BioSniper.
What is the prevalence of B-cell Acute Lymphoblastic Leukemia (B-ALL)?
The estimated prevalence of B-cell Acute Lymphoblastic Leukemia (B-ALL) is approximately 8.0 per 100,000 population.
Deep-dive into B-cell Acute Lymphoblastic Leukemia (B-ALL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis